Investors Overview
We’re Delivering the Promise of Healthier Lives.
Our Company
Corporate Profile
CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.
CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.
CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
Stock Today
Headquarters
CURE Pharmaceutical
1620 Beacon Place
Oxnard, CA 93033
Phone:
Fax:
We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.
Cure Pharmaceutical
Our Investor Presentation
Media
Recent Videos
CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020
CBD, Cannabis and the Cannabiz
In the news
Press Releases
CURE Pharmaceutical Letter to Shareholders
Investment in New Marketing Strategies Showing Encouraging Early ResultsEnhanced Instagram & Media campaigns featuring Nicole Kidman highlighting Seratopical RevolutionIncubator Strategy Initiated with New Market Disruptor Products arriving 1H2023SHERMAN OAKS, CA...
CURE Pharmaceutical Reports Third Quarter 2022 Results With Strong Sequential and Year Over Year Revenue Increases and Continued High Margins
New Marketing Programs Showing Encouraging Early ResultsSHERMAN OAKS, CA / November 22, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) ("CURE" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the...
Cure Pharmaceutical Holding to Present at the LD Micro Main Event XV
Presentation on Tuesday, October 25 at 12:30 PM Pacific Time (3:30 PM Eastern) Oxnard, California - Cure Pharmaceutical Holding Corp. (OTCQB: CURR) ("CURE"), a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical...
Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins
Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results OXNARD, Calif., Sept. 02, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary broad platform and...
CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman
Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience. Rob Costantino brings a unique...
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
OXNARD, Calif., Aug. 09, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive...
Management Team
Board of Directors
Key Contacts
Investor Relations
(805) 410-9962 ext. 4
investor@curepharma.com
Transfer Agent
Continental Stock Transfer & Trust
1 State Street 30th Floor
New York, NY 10004-1561
www.continentalstock.com
Auditors
RBSM, LLP
805 3rd Avenue #1430
New York, NY 10022
Corporate Counsel
Stradling Yocca Carlson & Rauth
660 Newport Center Drive
Suite 1600
Newport Beach, CA 92660
T: 949-725-4000
F: 949-725-4100